Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Rhea-AI Summary
Capricor Therapeutics announces completion of enrollment in Cohort A of Phase 3 trial for CAP-1002 in Duchenne Muscular Dystrophy, successful interim analysis, and plans for top-line data reporting in Q4 2024. The company also discloses upcoming FDA meeting for commercial manufacturing planning, expansion at San Diego facility, and 3-year data report in Q2 2024. Additionally, Capricor shares updates on a clinical trial collaboration with NIH, financial results, and corporate milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (CAPR) has secured an in-person Type-B meeting with the FDA to discuss its chemistry, manufacturing, and controls (CMC) plans for commercial launch, potentially expediting the Biologics License Application (BLA) submission. The company holds RMAT and orphan drug designations for CAP-1002 in Duchenne muscular dystrophy, aiming to accelerate approval pathways. With the Phase 3 HOPE-3 trial fully enrolled, Capricor is focused on swift approval and patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.6%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (CAPR) will host a conference call on February 29, 2024, to discuss its financial results for the fourth quarter and full year ended December 31, 2023. The company focuses on developing cell and exosome-based therapeutics for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces manufacturing scale-up for CAP-1002 and rapid enrollment in Phase 3 clinical trial. The company aims for commercial use with a new facility in San Diego and plans to discuss expedited approval with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) announced that its proprietary StealthX™ exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases will conduct a Phase 1 clinical study with Capricor’s vaccine, subject to regulatory approval. The vaccine is designed to deliver both the highly mutagenic S protein and the more stable N protein, potentially offering broader and longer-lasting immunity against SARS-CoV-2. The vaccine is free of both adjuvant and lipid nanoparticles and has generated a strong immune response at low doses in preclinical studies. This collaboration provides non-dilutive support for the advancement of Capricor’s vaccine candidate and highlights the clinical potential of the company's exosome platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces favorable interim futility analysis results for HOPE-3 trial evaluating CAP-1002 in patients with Duchenne muscular dystrophy. Successful completion triggers first milestone payment under U.S. agreement with Nippon Shinyaku. Enrollment complete for Cohort A with topline data expected in Q4 2024; Cohort B enrollment initiated. Plans to request FDA meeting in Q1 2024 for expedited approval pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
News
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) completes targeted enrollment for HOPE-3, Phase 3 trial of CAP-1002 in Duchenne Muscular Dystrophy. On track to report interim futility analysis in Q4 2023; Successful outcome triggers milestone payment. Positive FDA feedback confirms CAP-1002’s path towards Biologics License Application. Corporate update includes financial results, operational developments, and anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023, and will host a webcast and conference call at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Capricor Therapeutics to host webinar with Parent Project Muscular Dystrophy to discuss clinical trial of CAP-1002 for treating Duchenne muscular dystrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
Rhea-AI Summary
Capricor Therapeutics announces positive data supporting CAP-1002's efficacy in treating Duchenne Muscular Dystrophy and potential of StealthX™ technology for ASO delivery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
Capricor Therapeutics Inc
Nasdaq:CAPR
CAPR Rankings
CAPR Stock Data
513.86M
38.00M
16.84%
38.26%
17.96%
Biotechnology
Pharmaceutical Preparations
United States
BEVERLY HILLS